20 articles
A first-in-human trial shows CAR-modified stem cell memory T cells outperform standard CAR T cells in expansion, persistence, and complete responses.
Scientists develop innovative immunotherapy that reprograms multiple immune cell types to attack cancer while reducing side effects.
Engineered immune cells target harmful macrophages in tumors, transforming the cancer environment to boost natural anti-tumor immunity.
Scientists develop CAR T cells that attack tumor-supporting immune cells, showing promise for treating hard-to-target solid cancers.
A phase 1 trial shows Temferon β a gene-engineered stem cell therapy β safely delivers interferon-Ξ± into glioblastoma tumors with no dose-limiting toxicities.
New 3-D spatial mapping reveals four distinct immune-evasion niches in osteosarcoma that explain why checkpoint therapies fail.
Engineered immune cell vesicles first induce cancer cell senescence with chemo, then eliminate them with targeted senolytic drugs.
Researchers identify four LSC subtypes that predict venetoclax resistance and reveal matched subtype-specific therapies for AML patients.
BCG therapy for bladder cancer travels to bone marrow, reprogramming stem cells to produce enhanced immune cells that fight tumors throughout the body.
AML stem cells produce BHB via autonomous ketogenesis to block ferroptosis, revealing a targetable metabolic vulnerability in leukemia.
Scientists identify a mitochondria-proteasome-haem pathway that silences immune cells β and show bortezomib can fix it in CAR-T therapy.
New review reveals how targeting mitochondria in cancer cells could overcome immunotherapy resistance and enhance anti-tumor responses.
A large genomic study finds mesenchymal glioblastoma responds better to immune checkpoint blockade, opening a path to smarter patient selection.
A comprehensive review reveals how the senescence secretome suppresses tumors early but drives progression, resistance, and metastasis chronically.
A new Science paper reveals that mitochondrial fitness in dendritic cells controls antitumor immunity β and can be targeted to boost immunotherapy.
A sweeping review of CAR-T and CAR-NK cell therapies in acute myeloid leukemia, covering clinical trial outcomes, key targets, and next-gen strategies.
Harvard researchers demonstrate that activated macrophages can both trigger immune responses and infiltrate tumors directly.
Leukemic stem cells produce their own ketone bodies to block ferroptosis, revealing a metabolic weak point that could be targeted therapeutically.
New approach targets specific cancer sites in advanced lung cancer patients, potentially improving outcomes.
A novel cell-labeling tool reveals how ERΞ±+ macrophages create immune-excluded niches in bone, blocking T cells from destroying cancer.
